Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes

Chemico-Biological Interactions

Volumn 205, Issue 1, 2013, Pages 11-19

  Bae, Soo Hyeon ^a   Kwon, Min Jo ^a   Choi, Eu Jin ^a   Zheng, Yu Fen ^b   Yoon, Kee Dong ^a   Liu, Kwang Hyeon ^c   Bae, Soo Kyung ^a  

^a The Catholic University of Korea   (South Korea)

^b Seoul National University   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

Cocktail assay; CYP2B6; Human liver microsomes; LC MS MS; Potent inhibitor; Sibutramine

Indexed keywords

AMFEBUTAMONE; CHLORPROPAMIDE; COUMARIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DEXTROMETHORPHAN; MEPHENYTOIN; MIDAZOLAM; PACLITAXEL; PHENACETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SIBUTRAMINE; TOLBUTAMIDE;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING; FEMALE; HUMAN; HYDROXYLATION; IC 50; IN VITRO STUDY; LIVER MICROSOME; MALE;

COCKTAIL ASSAY; CYP; CYP2B6; CYTOCHROME P450; HUMAN LIVER MICROSOMES; IC(50); INHIBITION CONSTANT; K(I); LC-MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; POTENT INHIBITOR; SIBUTRAMINE; THE 50% INHIBITORY CONCENTRATION;

ARYL HYDROCARBON HYDROXYLASES; CYCLOBUTANES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; HUMANS; KINETICS; MALE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; THIOTEPA;

EID: 84879806226     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2013.06.006     Document Type: Article

References (49)

1. L.E. Korhonen, M. Turpeinen, M. Rahnasto, C. Wittekindt, A. Poso, O. Pelkonen, H. Raunio, and R.O. Juvonen New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis Br. J. Pharmacol. 150 2007 932 942 (Pubitemid 46536632)
2. S.E. Clarke, and B.C. Jones Human cytochromes P450 and their role in metabolism-based drug-drug interactions A.D. Rodrigues, Drug-Drug Interactions 2002 Marcel Dekker New York 55 88
3. S.E. Leucuta, and L. Vlase Pharmacokinetics and metabolic drug interactions Curr. Clin. Pharmacol. 1 2006 5 20
4. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F.P. Guengerich Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J. Pharmacol. Exp. Ther. 270 1994 414 423 (Pubitemid 24229655)
5. M.T. Baker, M.J. Olson, Y. Wang, W.C. Ronnenberg Jr., J.T. Johnson, and A.N. Brady Isoflurane-chlorodifluoroethene interaction in human liver microsomes: role of cytochrome P4502B6 in potentiation of halothane metabolism Drug Metab. Dispos. 23 1995 60 64
6. E.L. Code, C.L. Crespi, B.W. Penman, F.J. Gonzalez, T.K. Chang, and D.J. Waxman Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation Drug Metab. Dispos. 25 1997 985 993 (Pubitemid 27357697)
7. S. Ekins, and S.A. Wrighton The role of CYP2B6 in human xenobiotic metabolism Drug Metab. Rev. 31 1999 719 754 (Pubitemid 29390407)
8. D.M. Stresser, and D. Kupfer Monospecific antipeptide antibody to cytochrome P-450 2B6 Drug Metab. Dispos. 27 1999 517 525 (Pubitemid 29177646)
9. X. Ding, and L.S. Kaminsky Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts Annu. Rev. Pharmacol. Toxicol. 43 2003 149 173 (Pubitemid 37372638)
10. S. Miksys, C. Lerman, P.G. Shields, D.C. Mash, and R.F. Tyndale Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain Neuropharmacology 45 2003 122 132 (Pubitemid 36700458)
11. V. Lamba, L. Lamba, K. Yasuda, S. Storm, J. Davila, M.L. Hancock, J.D. Fackenthal, P.K. Rogan, B. Ring, S.A. Wrighton, and E.G. Schuetz Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression J. Pharmacol. Exp. Ther. 307 2003 906 922 (Pubitemid 37494207)
12. T. Lang, K. Klein, J. Fischer, A.K. Nüssler, P. Neuhaus, U. Hofmann, M. Eichelbaum, M. Schwab, and U.M. Zanger Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver Pharmacogenetics 11 2001 399 415 (Pubitemid 32656581)
13. D. Nolan, E. Phillips, and S. Mallal Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance Clin. Infect. Dis. 42 2006 408 410 (Pubitemid 43122321)
14. S. Rendic, and F.J. di Carlo Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors Drug Metab. Rev. 29 1997 413 580 (Pubitemid 27293618)
15. M. Turpeinen, H. Raunio, and O. Pelkonen The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico Curr. Drug Metab. 7 2006 705 714 (Pubitemid 44509677)
16. S.R. Faudette, R.L. Hawke, E.L. Lecluyse, S.S. Shord, B. Yan, R.M. Laethem, and C.M. Lindley Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity Drug Metab. Dispos. 28 2000 1222 1230
17. L.M. Hesse, K. Venkatakrishnan, M.H. Court, L.L. Von Moltke, S.X. Duan, R.I. Shader, and D.J. Greenblatt CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interaction with other antidepressants Drug Metab. Dispos. 28 2000 1176 1183
18. T.K.H. Chang, G.F. Weber, C.L. Crespi, and D.J. Waxman Differential activation of cyclophosphamide and ifosphamide by cytochrome P-450 2B and 3A in human liver microsomes Cancer Res. 53 1993 5629 5637 (Pubitemid 23360263)
19. J.M. Rae, N.V. Soukhova, D.A. Flockhart, and Z. Desta Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism Drug Metab. Dispos. 30 2002 525 530 (Pubitemid 34456973)
20. P. Roy, L.J. Yu, C.L. Crespi, and D.J. Waxman Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles Drug Metab. Dispos. 27 1999 655 666 (Pubitemid 29252439)
21. B.A. Ward, J.C. Gorski, D.R. Jones, S.D. Hall, D.A. Flockhart, and Z. Desta The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity J. Pharmacol. Exp. Ther. 306 2003 287 300 (Pubitemid 36734384)
22. Y. Hijazi, and R. Boulieu Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes Drug Metab. Dispos. 30 2002 853 858 (Pubitemid 34671099)
23. S. Crettol, J.J. Déglon, J. Besson, M. Croquette-Krokkar, I. Gothuey, R. Hämmig, M. Monnat, H. Hüttemann, P. Baumann, and C.B. Eap Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment Clin. Pharmacol. Ther. 78 2005 593 604 (Pubitemid 41773635)
24. E.D. Kharasch, C. Hoffer, D. Whittington, and P. Sheffels Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone Clin. Pharmacol. Ther. 76 2004 250 269 (Pubitemid 39221799)
25. M.H. Court, S.X. Duan, L.M. Hesse, K. Venkatakrishnan, and D.J. Greenblatt Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes Anesthesiology 94 2001 110 119 (Pubitemid 32055186)
26. M. Hidestrand, M. Oscarson, J.S. Salonen, L. Nyman, O. Pelkonen, M. Turpeinen, and M. Ingelman-Sundberg CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes Drug Metab. Dispos. 29 2001 1480 1484 (Pubitemid 33000696)
27. K. Kobayashi, T. Ishizuka, N. Shimada, Y. Yoshimura, K. Kamijima, and K. Chiba Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro Drug Metab. Dispos. 27 1999 763 766 (Pubitemid 29297771)
28. R.S. Obach, L.M. Cox, and L.M. Tremaine Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidase, and glucuronyl transferases in human: an in vitro study Drug Metab. Dispos. 33 2005 262 270 (Pubitemid 40216594)
29. S.K. Bae, S. Cao, K. Seo, H. Kim, M.J. Kim, J.H. Shon, K.H. Liu, H. Zhou, and J.G. Shin Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N, N-dimethylamine) metabolites in human liver microsomes Drug Metab. Disopos. 36 2008 1679 1688
30. J.M. Hutzler, D.M. Messing, and L.C. Wienkers Predicting drug-drug interactions in drug discovery: where are we now and where are we going Curr. Opin. Drug. Discov. Dev. 8 2005 51 58 (Pubitemid 40116330)
31. O. Pelkonen, and H. Raunio In vitro screening of drug metabolism during drug development: can we trust the predictions Expert Opin. Drug. Metab. Toxicol. 1 2005 49 59
32. R.L. Walsky, and R.S. Obach A comparison of 2-phenyl-2-(1-piperidinyl) propane (PPP),1,1′,1″-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6 Drug Metab. Dispos. 35 2007 2053 2059 (Pubitemid 350005195)
33. Z. Guo, S. Raeissi, R.B. White, and J.C. Stevens Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes Drug Metab. Dispos. 25 1997 390 393 (Pubitemid 27120588)
34. T. Richter, T.E. Mürdter, G. Heinkele, J. Pleiss, S. Tatzel, M. Schwab, M. Eichelbaum, and U. Zanger Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine J. Pharmacol. Exp. Ther. 308 2004 189 197 (Pubitemid 38090717)
35. M. Turpeinen, R. Nieminen, T. Juntunen, P. Taavitsainen, H. Raunio, and O. Pelkonen Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro Drug Metab. Dispos. 32 2004 626 631 (Pubitemid 38668155)
36. J. Chun, U.M. Kent, R.M. Moss, L.M. Sayre, and P.F. Hollenberg Mechanism-based inactivation of cytochrome P450 2B1 and 2B6 by 2-phenyl-2-(1-piperidinyl)propane Drug Metab. Dispos. 28 2000 905 911 (Pubitemid 30612608)
37. E. Harleton, M. Webster, N.N. Bumpus, U.M. Kent, J.M. Rae, and P.F. Hollenberg Metabolism of N, N′, N″-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms J. Pharmacol. Exp. Ther. 310 2004 1011 1019 (Pubitemid 39108922)
38. T. Richter, M. Schwab, M. Eichelbaum, and U.M. Zanger Inhibition of human CYP2B6 by N, N′, N″-triethylenethiophosphoramide is irreversible and mechanism-based Biochem. Pharmacol. 69 2005 517 524 (Pubitemid 40094510)
39. M.J. Kim, H. Kim, I.J. Cha, J.S. Park, J.H. Shon, K.H. Liu, and J.G. Shin High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry Rapid Commun. Mass Spectrom. 19 2005 2651 2658 (Pubitemid 41338608)
40. R. Yuan, S. Madani, X.X. Wei, K. Reynolds, and S.M. Huang Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions Drug. Metab. Dispos. 30 2002 1311 1319 (Pubitemid 35397032)
41. Draft FDA Guidance for Industry, 2006. Available from: < http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm080499.htm >.
42. R.S. Obach, R.L. Walsky, and K. Venkatakrishnan Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions Drug Metab. Dispos. 35 2006 246 255
43. W. Pan, S.K. Bae, E.J. Shim, S.E. Park, S.S. Lee, S.J. Park, C.W. Yeo, H.H. Zhou, J.H. Shon, and J.G. Shin Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolite M1 and M2 in relation to CYP2B6â̂ - 6 polymorphism Xenobiotica 43 2013 211 218
44. I.H. Segel Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Systems 1975 Wiley New York, NY
45. H. Akaike An information criterion (AIC) Math. Sci. 14 1976 5 9
46. Y.L. Han, H.L. Yu, D. Li, X.L. Meng, Z.Y. Zhou, Q. Yu, X.Y. Zhang, F.J. Wang, and C. Guo Inhibitory effects of limonin on six human cytochrome P450 enzymes and P-glycoprotein in vitro Toxicol. In Vitro 25 2011 1828 1833
47. J.M. Margolis, and R.S. Obach Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions Drug Metab. Dispos. 31 2003 606 611 (Pubitemid 36444170)
48. T.J. Yang, K.W. Krausz, M. Shou, S.K. Yang, J.T. Buters, F.J. Gonzalez, and H.V. Gelboin Inhibitory monoclonal antibody to human cytochrome P450 2B6 Biochem. Pharmacol. 55 1998 1633 1640 (Pubitemid 28223455)
49. E.T. Ogburn, D.R. Jones, A.R. Masters, C. Xu, Y. Guo, and Z. Desta Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation Drug Metab. Dispos. 38 2010 1218 1229